SAYC welcomes HIV breakthrough but urges inclusive rollout

The South African Youth Council (SAYC) in the Chris Hani Region has welcomed the introduction of a new HIV prevention medicine, Lenacapavir, describing it as a significant step forward in the country’s fight against HIV.

In a media statement issued on 10 April 2026, the youth body said the six-monthly injectable treatment could bring new hope, particularly for young people and vulnerable groups who often struggle to maintain daily prevention methods.

Lenacapavir, recently introduced by the National Department of Health, is expected to strengthen existing HIV prevention efforts by offering a longer-lasting alternative to daily medication.

A shift towards youth-centred healthcare

SAYC Chris Hani highlighted the importance of placing young people at the centre of healthcare planning and delivery. The organisation said the introduction of the new medicine comes at a critical time, especially as communities continue to face overlapping health challenges such as HIV and tuberculosis.

The council referenced its recent engagement during World TB Day commemorations in Sakhisizwe Local Municipality, noting that integrated approaches to health remain essential.

According to the statement, tackling HIV effectively requires solutions that consider the lived realities of young people, including barriers such as stigma, poverty, and limited access to healthcare services.

Calls for clarity on rollout

While welcoming the innovation, SAYC Chris Hani raised concerns about the need for clear communication regarding how Lenacapavir will be rolled out.

The organisation stressed that without proper information, communities may struggle to access the treatment or fully understand how it works. It warned that a lack of clarity could undermine trust and reduce the potential impact of the intervention.

The council is calling on health authorities to ensure that the rollout process is transparent, accessible, and inclusive, particularly for those most at risk.

Focus on vulnerable groups

The statement emphasised that the success of Lenacapavir will depend heavily on how well it reaches vulnerable populations.

SAYC Chris Hani pointed out that structural challenges such as poverty, social stigma, and unequal healthcare access continue to affect prevention efforts. Addressing these issues, the organisation said, is critical to ensuring that the new treatment benefits those who need it most.

The council also highlighted the importance of designing programmes that actively support and empower young people, rather than treating them as passive recipients of care.

Monitoring and accountability needed

In addition to rollout concerns, SAYC Chris Hani called for ongoing monitoring and evaluation of the new medicine.

The organisation said tracking the effectiveness, safety, and uptake of Lenacapavir among young people will be key to ensuring accountability and improving outcomes over time.

It stressed that evidence-based approaches should guide future adjustments to the programme, ensuring that it delivers meaningful results.

Youth ready to play a role

SAYC Chris Hani said young people are ready to be active partners in driving change within their communities.

However, the organisation reiterated that this requires a people-centred approach from authorities, with transparency and collaboration at the core of implementation efforts.

The council concluded that while Lenacapavir represents a promising advancement in HIV prevention, its real impact will depend on how effectively it is introduced and integrated into communities.